STLN Financials

Income Statement
MetricQ3 2026
Revenue
169.8M
Cost of Revenue
139.1M
Gross Profit
30.7M
Operating Expenses
33.7M
R&D
0
SG&A
32.1M
Operating Income
-2982000
EBITDA
-1460000
Net Income
-15748000
EPS (Basic)
$-0.13
EPS (Diluted)
$-0.13
Shares (Diluted)
104.7M
Starling Oncology (STLN) — Financials